Last reviewed · How we verify
zonisamide low dose group
zonisamide low dose group is a Anticonvulsant / Antiepileptic agent Small molecule drug developed by Eisai Korea Inc.. It is currently FDA-approved for Epilepsy (adjunctive or monotherapy for partial seizures), Generalized tonic-clonic seizures.
Zonisamide inhibits multiple ion channels and carbonic anhydrase to reduce neuronal excitability and seizure activity.
Zonisamide is a small molecule that blocks the sodium channel alpha subunit, classified as a blocker. It is used as a monotherapy for partial epilepsies in children, with low and high dose groups being compared in clinical trials.
At a glance
| Generic name | zonisamide low dose group |
|---|---|
| Sponsor | Eisai Korea Inc. |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Sodium channels, calcium channels, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide is a sulfonamide anticonvulsant that blocks sodium and calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. The drug is effective across multiple seizure types and is used as adjunctive or monotherapy in epilepsy management.
Approved indications
- Epilepsy (adjunctive or monotherapy for partial seizures)
- Generalized tonic-clonic seizures
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia
- Cognitive impairment
- Nephrolithiasis
- Hypohidrosis
Key clinical trials
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Low and High Dose Zonisamide in Children as Monotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zonisamide low dose group CI brief — competitive landscape report
- zonisamide low dose group updates RSS · CI watch RSS
- Eisai Korea Inc. portfolio CI
Frequently asked questions about zonisamide low dose group
What is zonisamide low dose group?
How does zonisamide low dose group work?
What is zonisamide low dose group used for?
Who makes zonisamide low dose group?
What drug class is zonisamide low dose group in?
What development phase is zonisamide low dose group in?
What are the side effects of zonisamide low dose group?
What does zonisamide low dose group target?
Related
- Drug class: All Anticonvulsant / Antiepileptic agent drugs
- Target: All drugs targeting Sodium channels, calcium channels, carbonic anhydrase
- Manufacturer: Eisai Korea Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Epilepsy (adjunctive or monotherapy for partial seizures)
- Indication: Drugs for Generalized tonic-clonic seizures
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing